Abstract

Aim: HSP60 has previously been shown to be an independent risk factor for congestive heart failure. Recently, increased HSP60 values have been shown to be associated with increased mortality in patients hospitalized with acute heart failure. The purpose of our study was to determine whether HSP 60 is an independent predictor of in-hospital or short-term mortality in patients with acute ST segment elevation myocardial infarction (STEMI) and to assess whether it may be used as an early predictor of in-hospital heart failure or cardiogenic shock development in the same population. Methods: A total of 221 patients over 18 years of age presenting within 12 hours after the onset of symptoms with STEMI between 2011 and 2013 were enrolled to our study. Our study was designed as a prospective cohort. Several clinical conditions, such as clinical heart failure, development of cardiogenic shock and death during hospitalization were recorded together with the data pertaining to the length of hospital stay, MI localization, revascularization strategy and risk factors associated with coronary heart disease. Patients were called 1 month after discharge to find out if anyone had died. Results: HSP 60 values were significantly higher in patients who died during hospitalization (P=0.004) or within 1 month after discharge (P=0.020). These results were independent from other factors associated with mortality following STEMI. Significant association was found between HSP60 value and in-hospital development of cardiogenic shock (P=0.03) or heart failure (P=0.03). Conclusion: HSP60 was found to be independently associated with increased mortality in patients admitted for STEMI and therefore may be used as a promising predictor of mortality.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call